Search | Clinical Trials Finder

Conditions: Non Small Cell Lung Cancer Stage IIIB
Interventions: Nivolumab, Nivolumab+Gemcitabine; Biological · Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan, Ivonescimab, Leucovorin Calcium, Magnetic Resonance Imaging, Muzastotug; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib, Sacituzumab tirumotecan, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 5
States / cities: Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more

Conditions: Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions: ITIL-306; Biological
Lead sponsor: Instil Bio; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri • New York, New York

Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more

Conditions: Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: K27M peptide, Nivolumab; Biological · Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 3 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 14
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more

Conditions: Pancreatic Cancer
Interventions: Oxaliplatin, Irinotecan, Folinic Acid, 5-Fluorouracil (5-FU), NC410, Nivolumab, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Biopsy, Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule, Metronidazole, Neomycin, Nivolumab, Pembrolizumab, Questionnaire Administration, Vancomycin; Procedure · Drug · Biological + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Abexinostat, Pembrolizumab; Drug · Biological
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-small Cell Lung Cancer
Interventions: Trabedersen, Pembrolizumab; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Colorectal Cancer Metastatic
Interventions: Balstilimab (BAL), Botensilimab (BOT), agenT-797; Drug
Lead sponsor: Darren Sigal, MD; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Glioblastoma (GBM)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Temozolomide (TMZ), Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Billiary Track Cancer
Interventions: Gemcitabine, Cisplatin, Pembrolizumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Neoplasm
Interventions: SAR441000, Cemiplimab REGN2810; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Boston, Massachusetts • Cleveland, Ohio • Houston, Texas

Conditions: Solid Tumor
Interventions: Atezolizumab, GDC-0919; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 6 more

Conditions: Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma
Interventions: Talimogene Laherparepvec (T-VEC), Pembrolizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 5
States / cities: Menlo Park, California • Stanford, California • Harrison, New York + 2 more

Conditions: Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions: rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan; Drug · Procedure · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumor
Interventions: SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide); Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 67
States / cities: Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 61 more

Conditions: Selected Advanced Solid Tumors
Interventions: EOS006215, Anticancer agent; Drug
Lead sponsor: iTeos Belgium SA; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Denver, Colorado • Sarasota, Florida

Conditions: Solid Tumor, Adult
Interventions: DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy; Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 16
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 13 more

Conditions: Metastatic Prostatic Adenocarcinoma
Interventions: Opdivo Injectable Product, Yervoy Injectable Product, Cytoxan, Cryosurgical freezing (cryosurgery); Drug · Procedure
Lead sponsor: Rampart Health, L.L.C.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Lancaster, California • Rochester, Michigan

Conditions: Basal Cell Carcinoma
Interventions: Nivolumab, Ipilimumab, Relatlimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

ITIL-306 in Advanced Solid Tumors

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Study of SRF617 in Patients With Advanced Solid Tumors

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

Study of DF1001 in Patients With Advanced Solid Tumors

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma